MOTS-c · Research brief

Liraglutide vs Retatrutide: What Trial Data Shows

Real Peptides Research TeamEditorial

Updated September 28, 20269 min read

55 WORDS

Short answer

Liraglutide, approved by the FDA in 2010 as Victoza and in 2014 as Saxenda, hits one receptor. Retatrutide hits three. That single structural difference is the entire story behind why the liraglutide vs retatrutide question keeps surfacing in research forums, and why the comparison is not a fair fight in the way most people assume.

Key takeaways

Liraglutide is a single GLP-1 receptor agonist approved by the FDA in 2010, while retatrutide is an investigational triple agonist that no regulatory agency has approved.
The liraglutide vs retatrutide gap is driven by glucagon receptor agonism, which adds an energy-expenditure mechanism that GLP-1-only compounds cannot access.
Liraglutide has completed cardiovascular outcomes data; retatrutide's long-term safety profile is still being characterised in ongoing Phase 3 research.
Retatrutide vs Mounjaro and retatrutide vs Zepbound are both comparisons against tirzepatide, the dual GLP-1/GIP agonist and the closest approved structural analogue.
Retatrutide vs insulin is a mechanistic mismatch, since insulin replaces a hormone while incretin agonists amplify a glucose-dependent pathway.
Every retatrutide compound available from research suppliers, including Real Peptides, is research use only and is not for human or veterinary use.

Our team supplies research-grade compounds to laboratories studying incretin biology, and the same question lands in our inbox weekly. Here's what the published literature actually supports.

What is the difference between liraglutide vs retatrutide?

Liraglutide is an FDA-approved GLP-1 receptor agonist requiring daily administration in clinical use. Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, studied with a roughly weekly schedule in trials. Retatrutide is not approved by any regulatory agency and remains research use only.

The common oversimplification is that retatrutide is just a stronger liraglutide. It isn't. Adding glucagon receptor agonism introduces an energy-expenditure mechanism that liraglutide has no access to at all, which changes the side-effect profile as much as the efficacy profile. This piece covers receptor pharmacology, what the published trials report, how retatrutide compares against the full approved field, and the regulatory line researchers must not cross.

Three receptors versus one: the pharmacology gap

The liraglutide vs retatrutide difference starts at the receptor level, not the dose level. Liraglutide is a GLP-1 receptor agonist: an acylated analogue of human glucagon-like peptide-1 with a fatty acid chain that binds albumin, extending its half-life to roughly 13 hours. That half-life is why clinical protocols used daily administration rather than weekly.

Retatrutide (also written LY3437943) is a single peptide engineered to activate three receptors at once: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. GLP-1 agonism slows gastric emptying and signals satiety centres in the hypothalamus. GIP agonism appears to improve insulin sensitivity and may blunt the nausea signalling driven by GLP-1 alone. Glucagon receptor agonism is the genuinely novel arm, since it increases hepatic energy expenditure and fat oxidation rather than simply reducing intake.

That third arm is the crux of liraglutide vs retatrutide. Liraglutide works almost entirely on the intake side of the energy balance equation. Retatrutide, in the published research, operates on both intake and expenditure.

In our experience working with labs comparing incretin analogues, the receptor-selectivity data is where protocols diverge most, far more than the molecular weight or solubility profile of the lyophilised powder.

What the published trials report on each compound

The evidence bases behind liraglutide vs retatrutide are not comparable in maturity, and any honest comparison has to say so. Liraglutide has more than a decade of completed Phase 3 programmes behind it, including the SCALE weight-management trials and the LEADER cardiovascular outcomes trial published in the New England Journal of Medicine. Those are finished, peer-reviewed, and regulator-reviewed.

Retatrutide's public record is a Phase 2 obesity trial published in the New England Journal of Medicine in 2023, plus ongoing Phase 3 work under the TRIUMPH programme. Studies report substantially greater mean body-weight reduction in the higher retatrutide cohorts at 48 weeks than anything the liraglutide literature describes, which is the headline everyone quotes. The caveat everyone skips: Phase 2 trials are smaller, shorter, and selected for patients most likely to tolerate escalation. Effect sizes routinely compress in Phase 3.

Here's a nuance that gets lost in the retatrutide vs liraglutide comparisons circulating online. Cardiovascular outcomes data is the hardest endpoint in metabolic medicine, and liraglutide has it. Retatrutide does not yet. A compound can produce larger weight reduction and still have an unresolved safety question, because glucagon receptor agonism raises heart rate and hepatic glucose output, which is precisely what long-term trials exist to characterise.

Where retatrutide sits against the wider approved field

The liraglutide vs retatrutide question rarely arrives alone. Researchers are usually mapping the whole incretin landscape, so the same receptor logic applies across it.

Retatrutide vs Ozempic and retatrutide vs Wegovy are both retatrutide against semaglutide, a single GLP-1 agonist with a half-life of roughly one week. Same molecule, different brand and indication. Retatrutide vs Mounjaro and retatrutide vs Zepbound are both retatrutide against tirzepatide, a dual GLP-1/GIP agonist and the closest approved comparator in receptor terms. Our tirzepatide research page covers that dual-agonist pharmacology in more detail.

Retatrutide vs Trulicity and retatrutide vs dulaglutide are the same comparison, since dulaglutide is the molecule and Trulicity the brand. Dulaglutide vs retatrutide is a weekly GLP-1 agonist against a weekly triple agonist. Retatrutide vs exenatide and retatrutide vs Bydureon involve the oldest incretin mimetic in clinical use, derived from exendin-4, with Bydureon being the extended-release formulation. Retatrutide vs Victoza is simply the liraglutide comparison again under its diabetes brand name.

Retatrutide vs insulin is a category error worth naming plainly. Insulin replaces a hormone. Incretin agonists amplify a glucose-dependent signalling pathway, which is why hypoglycaemia risk profiles differ so sharply between the two classes.

Liraglutide vs Retatrutide: Receptor and Evidence Comparison

This table maps the pharmacology and regulatory status of each compound discussed. It matters because receptor count, not marketing category, predicts both efficacy ceiling and adverse-event profile.

Compound (brand)	Receptor targets	Regulatory status	Evidence maturity	Professional Assessment
Liraglutide (Victoza, Saxenda)	GLP-1 only	FDA-approved 2010 and 2014	Completed Phase 3 plus cardiovascular outcomes data	The most thoroughly characterised comparator in the class; the reference point every newer analogue is measured against
Retatrutide (LY3437943)	GLP-1, GIP, glucagon	Investigational, not approved anywhere; research use only	Published Phase 2 obesity data, Phase 3 ongoing	Largest reported effect sizes in the class, but long-term safety and cardiovascular endpoints remain unresolved
Semaglutide (Ozempic, Wegovy)	GLP-1 only	FDA-approved	Extensive Phase 3 plus outcomes trials	Sets the current approved benchmark for single-agonist weight reduction
Tirzepatide (Mounjaro, Zepbound)	GLP-1 and GIP	FDA-approved	Completed Phase 3 programmes	The closest approved analogue to retatrutide's design; the fairest structural comparison available
Dulaglutide (Trulicity) and exenatide (Byetta, Bydureon)	GLP-1 only	FDA-approved	Long post-marketing record	Older-generation agonists with smaller reported weight effects; still clinically relevant for glycaemic endpoints

What If: Research Sourcing and Comparison Scenarios

What if a supplier markets retatrutide as an approved alternative to liraglutide?

Treat that claim as a disqualifying signal and source elsewhere. Retatrutide has no marketing authorisation from the FDA, EMA, or any other agency, so any supplier describing it as approved, prescribable, or interchangeable with Victoza or Saxenda is either misinformed or deliberately misleading. Legitimate research suppliers label investigational compounds as research use only without exception.

What if the certificate of analysis doesn't match the compound identity?

Stop and verify the CAS number and molecular weight against the certificate before the material enters any protocol. Peptide identity errors are the most consequential sourcing failure in comparative incretin research, because a mislabelled analogue invalidates every downstream result. Real Peptides publishes third-party certificates of analysis for catalog compounds so identity and purity can be checked before procurement rather than after.

What if a study design needs both a single and a triple agonist arm?

Source both compounds from the same supplier and batch-document each one separately. Cross-supplier variability in purity and residual solvent content introduces a confound that no statistical adjustment cleanly removes. Our team has seen comparative incretin protocols undermined by exactly this, where the receptor difference gets attributed an effect that batch purity actually explains.

The Uncomfortable Truth About Cross-Compound Comparisons

Here's the honest answer: most liraglutide vs retatrutide comparisons circulating online are methodologically worthless. They lift a percentage from a liraglutide Phase 3 trial and a percentage from a retatrutide Phase 2 trial and put them side by side as if that constitutes evidence. Different populations, different durations, different escalation schedules, different endpoints, different statistical powering. No head-to-head randomised controlled trial directly comparing retatrutide and liraglutide has been published. Until one exists, any claim that one outperforms the other by a specific margin is inference dressed up as data.

The defensible statement is narrower and more useful: retatrutide's triple-agonist design gives it mechanisms liraglutide structurally lacks, and the published Phase 2 results are consistent with that.

What this means for laboratory procurement

Researchers comparing incretin analogues need compounds whose identity and purity are verifiable before the experiment starts, not inferred afterwards. The practical problem in the retatrutide supply market is that investigational compounds attract sellers who cut corners precisely because no regulator is auditing the product. Purity variance between batches, undeclared residual solvents, and outright identity substitution all show up in this segment.

Our approach is small-batch synthesis with exact amino-acid sequencing and publicly verifiable third-party testing, so a lab can confirm what it received. Compounds across our full research catalog carry certificates of analysis for that reason, whether the work involves incretin analogues or adjacent research compounds like BPC-157 and MOTS-c, which appears in metabolic research for unrelated mitochondrial signalling reasons.

Real Peptides does not provide preparation or administration guidance for any compound, because these are research-use-only materials intended for qualified laboratory settings. Concentration in a research context is simply mass per volume, expressed as milligrams per millilitre, and the certificate states the vial's stated mass content. That is where supplier information ends and the investigator's own protocol begins.

The liraglutide vs retatrutide comparison will look different in three years, and that is the point worth holding onto. Liraglutide's position is fixed because its Phase 3 and outcomes data are complete. Retatrutide's is provisional, and provisional means the number that gets quoted today may not survive contact with a larger population studied for longer. Anyone building a research programme around the triple agonist should design it to be informative regardless of which way the Phase 3 readouts land, because that is the only version of the work that stays valuable either way.

References

Peer-reviewed sources on Retatrutide indexed in PubMed, listed for research context. Real Peptides supplies Retatrutide for laboratory research use only.

Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proceedings (Baylor University. Medical Center), 2025. PMID 40291085. doi:10.1080/08998280.2025.2456441
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. Journal of basic and clinical physiology and pharmacology, 2025. PMID 40728138. doi:10.1515/jbcpp-2025-0113
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. European journal of clinical pharmacology, 2024. PMID 38367045. doi:10.1007/s00228-024-03646-0
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism open, 2024. PMID 39318607. doi:10.1016/j.metop.2024.100321
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, obesity & metabolism, 2026. PMID 41090431. doi:10.1111/dom.70209
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 2026. PMID 42250575. doi:10.1016/S0140-6736(26)00967-0
Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules, 2025. PMID 40563436. doi:10.3390/biom15060796
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology, 2025. PMID 40609566. doi:10.1016/S2213-8587(25)00092-0

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Liraglutide is a single GLP-1 receptor agonist, while retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. The glucagon arm is the key structural difference, since it engages energy expenditure and hepatic fat oxidation rather than only appetite and gastric emptying. Liraglutide is FDA-approved; retatrutide is investigational and research use only.

No. Retatrutide (LY3437943) has not received marketing authorisation from the FDA or any other regulatory agency and remains an investigational compound in ongoing Phase 3 research. Any supplier or website describing it as approved or prescribable is misrepresenting its status. All retatrutide sold by research suppliers is research use only and is not for human or veterinary use.

Mounjaro and Zepbound are both brand names for tirzepatide, a dual GLP-1 and GIP receptor agonist. Retatrutide adds a third receptor target, glucagon, making it the closest structural relative to tirzepatide among investigational compounds. Tirzepatide has completed Phase 3 programmes and holds FDA approval, whereas retatrutide's Phase 3 data is still being generated.

Not directly, because no published head-to-head randomised controlled trial has compared the two compounds. Liraglutide's evidence base includes completed Phase 3 weight-management programmes and cardiovascular outcomes data, while retatrutide's public record centres on a Phase 2 obesity trial published in the New England Journal of Medicine. Comparing percentages across trials with different populations and durations produces inference, not evidence.

Ozempic and Wegovy are both semaglutide, a single GLP-1 receptor agonist with a half-life of roughly one week. Retatrutide targets three receptors instead of one, which is why its reported Phase 2 effect sizes exceed what the semaglutide literature describes. Semaglutide has FDA approval and extensive outcomes data; retatrutide has neither yet.

They work through fundamentally different mechanisms. Insulin directly replaces or supplements a hormone the body may no longer produce sufficiently, acting regardless of blood glucose level. Incretin receptor agonists like retatrutide amplify a glucose-dependent signalling pathway, meaning their insulinotropic effect scales with circulating glucose, which is why hypoglycaemia risk profiles differ substantially between the two classes.

Exenatide (Byetta, with Bydureon as the extended-release formulation) is derived from exendin-4 and was the first incretin mimetic in clinical use. Dulaglutide is the molecule marketed as Trulicity, a weekly GLP-1 agonist. All are single-receptor GLP-1 agonists, so retatrutide vs exenatide and retatrutide vs dulaglutide are both comparisons of a triple agonist against first-generation single-target pharmacology.

No. Retatrutide is supplied strictly for laboratory research by qualified researchers and institutions, and is not intended for human or veterinary consumption. Real Peptides supplies research-use-only compounds to research settings only. Anyone seeking a weight-management or metabolic therapy should be working with a licensed prescribing physician using approved medications.

Pricing varies widely by supplier, vial mass, purity specification, and whether third-party testing is included. The meaningful cost variable is not the headline price but whether the compound arrives with a verifiable certificate of analysis confirming identity and purity, since an unverified vial that fails identity checks costs the full value of the experiment it invalidates.

No. Real Peptides does not supply preparation, administration, or protocol guidance for any catalog compound, because all materials are research use only and protocol design belongs to the investigating laboratory. What we do provide is verifiable compound identity: CAS number, molecular identity, and third-party certificates of analysis stating the vial's mass content so investigators can perform their own concentration calculations.

Verify the CAS number and molecular weight against a third-party certificate of analysis, confirm the stated purity percentage and the analytical method used, and check that the supplier labels the compound as research use only without therapeutic claims. Identity substitution and batch purity variance are the two failure modes most likely to invalidate comparative incretin research before the protocol even begins.

Glucagon receptor activation increases hepatic energy expenditure and fat oxidation, a mechanism that GLP-1-only compounds like liraglutide cannot access. This is why retatrutide's design targets both sides of the energy balance equation rather than intake alone. It is also why the safety questions differ: glucagon agonism can raise heart rate and hepatic glucose output, which is exactly what long-term trials are designed to characterise.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA